Zhifei to co-promote GSK's shingles vaccine in China

Shares of Chinese high-tech biological enterprise Chongqing Zhifei Biological Products (SHE: 3001220) leapt 20% to 58.40 renminbi, on the news that it will to co-promote UK pharma major GSK's (LSE: GSK) shingles vaccine, Shingrix in China for an initial three-year period, with the potential to extend the partnership should all parties agree.

Set to start January 1, 2024, Zhifei will have exclusive rights to import and distribute Shingrix in China, focusing on promoting the vaccine through its extensive service network, which covers more than 30,000 vaccination points across the country. In partnership, GSK - as the license holder for the product - will co-promote Shingrix by raising awareness of the importance of shingles vaccination amongst healthcare professionals within community health centres and hospital settings.

Financial considerations